Pharmacogenomic Analyses Implicate B Cell Developmental Status and MKL1 as Determinants of Sensitivity toward Anti-CD20 Monoclonal Antibody Therapy

Monoclonal antibody (mAb) therapy directed against CD20 is an important tool in the treatment of B cell disorders. However, variable patient response and acquired resistance remain important clinical challenges. To identify genetic factors that may influence sensitivity to treatment, the cytotoxic a...

Descripción completa

Detalles Bibliográficos
Autores principales: Small, George W., Akhtari, Farida S., Green, Adrian J., Havener, Tammy M., Sikes, Michael, Quintanhila, Julia, Gonzalez, Ricardo D., Reif, David M., Motsinger-Reif, Alison A., McLeod, Howard L., Wiltshire, Tim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297299/
https://www.ncbi.nlm.nih.gov/pubmed/37371044
http://dx.doi.org/10.3390/cells12121574

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297299/
https://www.ncbi.nlm.nih.gov/pubmed/37371044
http://dx.doi.org/10.3390/cells12121574

Ejemplares similares